SHANGHAI, June 24, 2024 /PRNewswire/ -- Hualing Pharmaceutical (“Company”, Hong Kong Stock Exchange stock code: 2552.HK) announced today that at the 84th American Diabetes Association (ADA) Scientific Annual Conference, the company and its wholly-owned subsidiary Nanjing Shengdreel Pharmaceutical Technology Co., Ltd. (Shengdreel) presented a number of basic research results. A basic study showed that the world's first novel double-acting glucokinase activator (GKA) reduces blood sugar levels by promoting the secretion of insulin and GLP-1. The hypoglycemic effect of the combination of doglitin and the SGLT-2 inhibitor caglagliflozin is superior to that of single medication, and has a synergistic effect. Other basic studies have shown that dogliatin has potential in preventing diabetes.

Doglitidine is the world's first glucokinase activator independently developed by Hualing Pharmaceutical. By repairing impaired glucokinase function and expression in type 2 diabetics, it enhances glucose sensitivity in type 2 diabetics, thereby improving patients' blood sugar homeostasis. Previous basic research and clinical studies have shown that its mechanism of action also includes improving GLP-1 secretion, restoring pancreatic function, and increasing liver insulin sensitivity. Canagliflozin (Canagliflozin) is an SGLT-2 inhibitor hypoglycemic drug. The purpose of this basic study is to evaluate the regulatory effect of the combination of the two drugs on glucose homeostasis in mice and to lay the foundation for clinical combination treatment.

The study began by administering the two drugs separately to mice to explore the mechanism of action of the two drugs. Research shows that caprolidine reduces glucose levels by blocking the kidney's reabsorption of glucose without affecting hormone secretion. Doglitidine lowers glucose levels by increasing the secretion of insulin and GLP-1. In combined drug use studies, the mechanism of action of both drugs was preserved, and the effects of combined medication were observed at different time points (including random, overnight fasting, and eating on an empty stomach). Both were superior to doglitin or caproxil alone, and had synergistic effects. Previous clinical studies by Hualing Pharmaceutical have also shown that the efficacy of using doglititin in combination with the SGLT-2 inhibitor Empagliflozin (Empagliflozin) is also superior to that used alone. In addition, the study also found that combined medication can stimulate glucagon secretion, which is expected to bring cardiovascular benefits.

The study provides a basis for basic research to guide physicians' clinical medication use, and also explores new possibilities for combined medication in terms of kidney function protection and cardiovascular benefits.

The company also reported on basic research conducted in collaboration with the Chinese University of Hong Kong to explore opportunities to reverse reduced glucose tolerance (IGT) to normal glucose tolerance (NGT) in China. By studying the effects of a single dose (50 mg) of dogliatetin on IGT patients and NGT subjects during hyperglycemic clamp tests, it was found that doglititin can increase second-phase insulin secretion in IGT patients and basal insulin secretion in NGT subjects, and also promotes the inhibitory effect of glucose on glucagon secretion in NGT subjects. Research shows that doglitidine has the potential to mechanically reverse IGT to NGT, thereby achieving the goal of preventing diabetes.

In addition, Hualing Pharmaceuticals and Shengdrel also presented other basic research results through posters, including studies on caglagliflozin stimulating glucagon secretion through direct effects on alpha cells under specific conditions. Glycine enhances glucose-stimulated insulin secretion by participating in the NMDA receptor pathway, providing a new direction for basic research on the island-central nervous system axis. The above research will further explore the clinical application potential of doglitin and expand Hualing Pharmaceutical's future product pipeline and disease fields.

About Hualing

Hualing Pharmaceutical is an innovative drug development and commercialization company headquartered in Shanghai, China. It has established companies in the US and Hong Kong, China. Hualing Pharmaceuticals focuses on unmet medical needs and develops new treatments for patients around the world. Hualing Pharmaceutical brings together high-quality talents from the global pharmaceutical industry, integrates innovative global technology, and relies on superior global resources to research and develop breakthrough technologies and products to lead global diabetes medical innovation. The company's core product Huatangning(Dogliatin tablets) target the glucose sensor glucokinase to enhance glucose sensitivity and improve blood sugar homeostasis in patients with type 2 diabetes. September 30, 2022, Hua Tang NingIt has obtained marketing approval from China's National Drug Administration (NMPA) for use alone or in combination with metformin to treat type 2 diabetes in adults. For patients with renal insufficiency, there is no need for dose adjustment. It is an oral hypoglycemic drug for type 2 diabetics with varying degrees of renal impairment (including end-stage kidney loss without dialysis). Hualing Pharmaceuticals will work with leading company Bayer to promote HuatangningCommercialization promotion in China to benefit diabetics and their families.

About Cendrell

Nanjing Shengdreier Pharmaceutical Technology Co., Ltd. is located in Biomedical Valley, Jiangbei New Area, Nanjing. It is a wholly-owned subsidiary of Hualing Pharmaceutical. The company focuses on research and development of new drugs for rare metabolic diseases. It aims to provide effective treatment plans for rare metabolic diseases represented by neonatal hypoglycemia, and also carry out auxiliary diagnosis services for rare diseases, including research on mutant gene function. The company has built a complete pre-clinical drug research and development technology platform, including computer-assisted drug screening, optimized compound synthesis, target protein function testing and compound screening, drug screening based on islet function, and pharmacodynamics determination in animal models of diseases, etc., and has laid out multiple R&D pipelines for different targets. The company was selected as a “technology-based private enterprise”, “small and medium-sized enterprise in science and technology” and “innovative small and medium-sized enterprise”. The company also undertook major national projects to create new drugs and cooperated with many well-known universities and research institutes at home and abroad to continuously expand exploration of disease mechanisms while developing innovative drugs.

Inquire for details
Hualing Pharmaceuticals
URL:
investor
Email: ir@huamedicine.com
presses
Email: pr@huamedicine.com